Obesity in the Russian Federation: epidemiology, socio-demographic and nutritional factors for development DOI Open Access
Martinchik An, A K Baturin, D B Nikityuk

et al.

Hygiene and Sanitation, Journal Year: 2024, Volume and Issue: 103(12), P. 1504 - 1513

Published: Dec. 27, 2024

Introduction. The increasing prevalence of obesity is a serious health problem, since significantly increases the risk diseases such as diabetes type 2, fatty liver disease, hypertension, myocardial infarction, stroke, dementia, osteoarthritis, obstructive sleep apnea, and some types cancer, in general, leads to significant reduction life expectancy. aim this study analyze adult population Russian Federation depending on socio-demographic factors dietary patterns for years observation from 1994 2023. Materials methods. current overweight aged 19+ during 2023 was assessed base body mass index (BMI) by anthropometric parameters weight height obtained Federal State Statistics Service (Rosstat) “Sample Survey Population Diets” over based random sample forty five thousand households all constituent entities (72,129 members households, 41% men 59% women). To trends obesity, results observations 1994–2012 under RLMS project data Rosstat part diet survey 2013–2023 were summarized. according WHO criteria analyzed variables: gender, age, place residence, level education, average per capita monthly household income. Results. Overweight (without BMI 25.0–29.9) found 52.5% 38.9% women. At same time, (BMI≥30.0) more common women than men, respectively, 24.2% 17.3%. total frequency overweight, including higher women, 69.8% 63.1%. Among rural residents, among urban residents. both settlements decreases with an increase number linearly age 19 65 years, group it begins decrease until 90 years. incidence sharply 35 then maintaining linear 55 In slowly 50 there rapid 65, then, decrease. young at 19–30 age. highest Ural Siberian Districts, 22.3% 20.7%, 27.9%, 28.5%. minimum North Caucasus District. people sexes wealthiest groups lower less wealthy (1st 2nd quintiles income). proportion obese only while series basic general education. Discussion. An analysis relationship between specific structure macronutrient energy consumption Russia 1994–2023 showed daily consumption, absolute values macronutrients % be individuals. A direct dependence due fat inverse carbohydrate clearly visible course observations. Limitations. limitations are determined registration 2013 indices respondents’ words without objective measurements weight, which should taken into account when interpreting obtained. Conclusion. association developing strategy priority measures prevent reduce individual levels

Language: Английский

Understanding the release mechanisms and secretion patterns for glucagon-like peptide-1 using the isolated perfused intestine as a model DOI Creative Commons
Katrine D. Galsgaard, Ida M. Modvig, Jens J. Holst

et al.

Biochemical Society Transactions, Journal Year: 2025, Volume and Issue: 53(01)

Published: Jan. 31, 2025

In the gastrointestinal (GI) tract, food is digested and absorbed while GI hormones are secreted from enteroendocrine cells (EECs). These regulate intake, glucose homeostasis, digestion, motility, metabolism. Although ECCs may express more than a single hormone, usually secrete only one or few hormones. The pattern of EEC secretion varies along length tract as different types scattered in densities tract. Following bariatric surgery, postprandial hypersecretion certain occurs which contributes to postsurgery weight loss. Mimicking this by targeting endogenous secretion, using specific modulators receptors, ion channels, transporters found on EECs, induce loss current research aim. To achieve this, complete understanding release mechanisms, expression transporters, ECC needed. Using vascularly perfused intestinal model, it possible obtain detailed knowledge these mechanisms evaluating effects blocking stimulating well nutrient handling absorption each sections intestine. This mini-review will focus how isolated intestine has been used our group model investigate nutrient-induced with glucagon-like peptide-1 secreting cells.

Language: Английский

Citations

0
Robotic versus open ventral hernia repair (ROVHR): a randomized controlled trial protocol DOI Creative Commons
Andreza Carvalho, Kimberly Woo, Ryan C. Ellis

et al.

Hernia, Journal Year: 2025, Volume and Issue: 29(1)

Published: March 4, 2025

Abstract Background Robotic retromuscular hernia repair has proven to be feasible and safe but lacks randomized data demonstrate significant clinical benefit. The majority of current comparative studies published have been case series, retrospective studies, systematic reviews, or large registry data, all which limitations bias (Bittner et al. in Surg Endosc 32:727–734. https://doi.org/10.1007/s00464-017-5729-0 , 2018; Bracale al Hernia 25:1471–1480. https://doi.org/10.1007/s10029-021-02487-5 2021; Carbonell Ann 267:210–217. https://doi.org/10.1097/SLA.0000000000002244 (Warren Endosc. https://doi.org/10.1007/s00464-024-11202-1 2024; Dewulf BJS Open 6:zrac057. https://doi.org/10.1093/bjsopen/zrac057 2022; Maskal Beffa Clin N Am 103:977–991. https://doi.org/10.1016/j.suc.2023.04.007 2023). It was only recently that the first trial conducted by Warren comparing open robotic repairs with synthetic mesh 2024). currently available yielded inconsistent outcomes leaving knowledge gaps for decision making. Reduced length stay a consistently outcome, however, therefore, we hypothesized would superior reducing hospital 24 h (Carbonell 2018). Methods Institutional Review Board at participating sites approved this protocol. This registered on clinicaltrials.gov (NCT: 05472987). ROVHR is registry-based, multicenter, double-blinded trial. primary hypothesis least h. Secondary include 30-day wound morbidity, readmissions, opioids prescribed consumed, NRS-11 pain scores obtained daily 5 days after surgery, PROMIS-3a Pain Intensity survey, patient reported including Hernia-Related Quality Life (HerQLes), EuraHS. Additionally, direct operating room costs will compared. Discussion Based existing literature, designed endpoint determine if reduce compared repairs. study add high-level evidence providing evidence-based Trial registration NCT05472987. Registered July 20, 2022.

Language: Английский

Citations

0
Robotic retromuscular hernia repair optimizes short-term outcomes in higher risk patients DOI
Keith Makhecha,

Sathvik Madduri,

A. Anderson

et al.

Surgical Endoscopy, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Language: Английский

Citations

0
Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management DOI

Amruth Akhil Alluri,

Yashaswi Guntupalli,

Shruti Suresh Suvarna

et al.

Journal of Basic and Clinical Physiology and Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Abstract Incretin-based medicines have considerably impacted the treatment of type 2 diabetes mellitus (T2DM), providing considerable advantages in glycemic regulation, weight control, and cardiovascular results. This narrative review examines progress incretin medicines, encompassing glucagon-like peptide-1 (GLP-1) receptor agonists, dual-receptor, triple-receptor while emphasizing their therapeutic advantages, obstacles, prospective developments. The examined articles were sourced from databases including PubMed Google Scholar, concentrating on publications predominantly 2010 to 2024. Selective foundational papers released before this timeline incorporated furnish critical historical context about processes discovery. despite efficacy, encounter hurdles elevated costs, patient compliance difficulties, variability response attributable genetic physiological variables. Moreover, there are still deficiencies comprehending long-term safety cancer risks linked these medicines. Emerging dual- agonists demonstrate potential overcoming shortcomings conventional GLP-1 enhanced metabolic results broader uses intricate disease profiles. Future research must concentrate economic streamlined regimens, customized medicine, integration artificial intelligence, stratification, as well efficacy incretin-based for holistic management T2DM.

Language: Английский

Citations

0
Unveiling the Cost-Effectiveness of Bariatric Surgery: Insights from a Matched Cohort Study DOI
Samuel Lloyd, Elizabeth Wall‐Wieler, Yuki Liu

et al.

Surgery for Obesity and Related Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
OBESITY AND MITOCHONDRIAL UNCOUPLING – AN OPPORTUNITY FOR THE CARBON MONOXIDE-BASED PHARMACOLOGY OF METABOLIC DISEASES DOI Creative Commons
Aleksandra Danielak, Marcin Magierowski

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107741 - 107741

Published: April 1, 2025

Language: Английский

Citations

0
Pediatric Metabolic and Bariatric Surgery and Anti-Obesity Medications: Weighing Efficacy, Risks, and Future Directions DOI
Justine Chinn,

Jennifer Woo Baidal,

Janey Pratt

et al.

The Journal of Pediatrics, Journal Year: 2025, Volume and Issue: unknown, P. 114610 - 114610

Published: April 1, 2025

Language: Английский

Citations

0
Great Debates: Undergoing the Knife versus Pill-Popping—The Comparative Efficacy and Cost-Effectiveness of Bariatric Surgery and GLP-1 Receptor Agonists in the Management of Obesity DOI

Paul J. Brosnihan,

M. Siobhan Luce,

Amy Yetasook

et al.

The American Surgeon, Journal Year: 2025, Volume and Issue: unknown

Published: April 26, 2025

Bariatric surgery has long been the most effective intervention for obesity, providing significant and durable weight loss, with procedures like sleeve gastrectomy gastric bypass achieving 10-year total loss (TWL) rates of 23.4% 26.9%, respectively. More complex procedures, such as duodenal switch, result in even greater TWL. Recently, glucagon-like peptide-1 receptor agonists (GLP-1 RA) have emerged a promising pharmacological alternative, demonstrating up to 25.3% TWL tirzepatide. However, GLP-1 RA efficacy remains inferior bariatric surgery, high discontinuation due adverse effects, cost, limited insurance coverage. While offers superior long-term outcomes cost-effectiveness, it is underutilized, less than 1% eligible patients undergoing surgical annually. can expand access obesity treatment, particularly hesitant or ineligible may serve bridge an adjunct postoperative regain. Despite their benefits, RAs require sustained adherence, regain common upon discontinuation. A multidisciplinary approach integrating surgical, pharmacological, lifestyle interventions essential optimizing management. Future research should focus on efficacy, combination therapy strategies, improving both medical treatments.

Language: Английский

Citations

0
Patients With Severe Obesity Are Made Eligible for Complex Abdominal Wall Repair After Preoptimization With GLP‐1 Agonists: Results of a Bicentric Pilot Study DOI Creative Commons
B. Romain,

Vincent Pfirsch,

Simone Manfredelli

et al.

World Journal of Surgery, Journal Year: 2025, Volume and Issue: unknown

Published: March 15, 2025

ABSTRACT Background Incisional hernia repairs (IHRs) are not recommended in patients with severe obesity (BMI ≥ 35 kg/m 2 ). Weight loss is challenging, but new medications, such as glucagon‐like peptide‐1 receptor agonists (GLP‐1 agonists), have recently attracted increased attention for their potential weight advantages. The aim was to analyze the preliminary results about safety and efficiency of use GLP‐1 context prehabilitation prior complex IHR. Methods All planned IHR a BMI treated preoperative were included experimental group compared comparable historical surgical cohort conventional tailored nutritional management. perioperative postoperative outcomes between two groups. success rate GLP1 defined that enables patient fall within limits ≤ before an Results Fifty‐two control 24 agonists. distribution follows: semaglutide ( n = 12; 50%), dulaglutide 7; 29.2%), liraglutide 5; 20.8%). mean initial 40.1 ± 3.6 . average percentage 11.3 7.4% (maximum observed 2.4 mg/wk). (defined IHR) reached 15/24 (62.5%). Postoperative total complication lower (59.6% vs. 45.8% p 0.2). Conclusion This study demonstrated efficacy optimization obesity, allowing thirds benefit from IHR, tendency morbidity. Trial Registration: CPP Mediterranee, n° 21.00430.000004.

Language: Английский

Citations

0
GLP-1 medications versus surgery and balloon: evaluating cost-benefit in weight loss DOI Open Access
Carlos Salazar, Secundino López,

Camilo Rı́os

et al.

International Surgery Journal, Journal Year: 2025, Volume and Issue: 12(5), P. 884 - 891

Published: April 25, 2025

This narrative review compares three prominent interventions-GLP-1 receptor agonists (e.g., semaglutide), laparoscopic sleeve gastrectomy (LSG), and intragastric balloon therapy-regarding their clinical efficacy cost-effectiveness. Drawing on recent meta-analyses, professional guidelines, economic modeling studies from 2023-2025, we synthesize key findings related to weight loss outcomes, comorbidity resolution, long-term value. Bariatric surgery, particularly LSG, achieves the most substantial durable (~20-30% of total body weight) offers superior benefits, including diabetes remission reduced cardiovascular risk. Despite high initial costs, it is consistently found be cost-effective or cost-saving over time, in patients with diabetes. GLP-1 produce meaningful (~10-15%) metabolic improvement but are associated significant ongoing costs potential regain after discontinuation, limiting Intragastric therapy less invasive lower immediate cost, moderate (~10-15% loss), typically results temporary benefits limited insurance coverage. As a standalone therapy, its cost-effectiveness inferior though suggests value when used as pre-surgical adjunct. Overall, LSG emerges intervention severe obesity, while therapy’s depends heavily duration pricing. balloons may viable for specific subpopulations preparatory contexts. Tailoring selection based both parameters essential sustainable obesity management. Further research warranted refine cost-benefit assessments new therapies pricing models evolve.

Language: Английский

Citations

0